A photo of Pooja Khandelwal.

Member, Division of Bone Marrow Transplantation and Immune Deficiency

Associate Professor, UC Department of Pediatrics



Board Certified

About Me


Becoming a physician and researcher has fulfilled my desire to help others. Early in my residency, I was drawn to pediatric hematology-oncology and later, during my fellowship, I became interested in bone marrow transplantation. I continue to enjoy working with children because it’s very rewarding to see a sick child turn the corner and do well.

In patient care, I specialize in bone marrow transplantation for hemoglobinopathies, malignancies and metabolic disorders. I also run a multidisciplinary clinic focused on taking care of children with chronic graft versus host disease. With my research, I work to restore and maintain intestinal homeostasis in patients during the peri-transplant period.

My goal is to reduce the incidence of graft versus host disease (GVHD) by using a variety of approaches, such as administration of specific nutritional compounds and modification of the intestinal microbiome. Since GVHD can be a life-threatening complication after bone marrow transplants, I am interested in improving outcomes for patients by reducing its occurrence.

Additional Languages


Clinical Interests

Pediatric bone marrow transplantation; acute graft versus host disease

Research Interests

Acute graft versus host disease biology; treatment of steroid refractory acute graft versus host disease; management of refractory autoimmune cytopenias in the post-transplant setting

Academic Affiliation

Associate Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Bone Marrow Transplantation BMT

My Locations

My Education

MD: Kasturba Medical College, Manipal, India, 2005.

Residency: University of Arizona College of Medicine, Tucson, AZ, 2010.

Fellowship: Cincinnati Children's Hospital Medical Center, 2013.

My Publications

Selected Publication

CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Khandelwal, P; Fukuda, T; Teusink-Cross, A; Kashuba, AD M; Lane, A; Mehta, PA; Marsh, RA; Jordan, MB; Grimley, MS; Myers, KC; et al. Bone Marrow Transplantation. 2020; 55:1552-1559.

Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience. Teusink-Cross, A; Davies, SM; Grimley, MS; Chandra, S; Flannery, A; Dandoy, CE; Nelson, AS; Marsh, RA; Jacoby, B; Lane, A; et al. Pediatric Transplantation. 2020; 24.

CD38brightCD8+ T Cells Associated with the Development of Acute GVHD Are Activated, Proliferating, and Cytotoxic Trafficking Cells. Khandelwal, P; Chaturvedi, V; Owsley, E; Lane, A; Heyenbruch, D; Lutzko, CM; Leemhuis, T; Grimley, MS; Nelson, AS; Davies, SM; et al. Biology of Blood and Marrow Transplantation. 2020; 26:1-6.

A Pilot Study of Human Milk to Reduce Intestinal Inflammation After Bone Marrow Transplant. Khandelwal, P; Andersen, H; Romick-Rosendale, L; Taggart, CB; Watanabe, M; Lane, A; Dandoy, CE; Lake, KE; Litts, BA; Morrow, AL; et al. Breastfeeding Medicine. 2019; 14:193-202.

Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. Khandelwal, P; Millard, HR; Thiel, E; Abdel-Azim, H; Abraham, AA; Auletta, JJ; Boulad, F; Brown, VI; Camitta, BM; Chan, KW; et al. Biology of Blood and Marrow Transplantation. 2017; 23:1342-1349.

Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients. Khandelwal, P; Teusink-Cross, A; Davies, SM; Nelson, AS; Dandoy, CE; El-Bietar, J; Marsh, RA; Kumar, AR; Grimley, MS; Jodele, S; et al. Biology of Blood and Marrow Transplantation. 2017; 23:1122-1127.

A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Khandelwal, P; Emoto, C; Fukuda, T; Vinks, AA; Neumeier, L; Dandoy, CE; El-Bietar, J; Chandra, S; Davies, SM; Bleesing, JJ; et al. Biology of Blood and Marrow Transplantation. 2016; 22:2220-2225.

A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease. Khandelwal, P; Bleesing, JJ; Davies, SM; Marsh, RA. Biology of Blood and Marrow Transplantation. 2016; 22:2011-2018.

A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. Khandelwal, P; Fukuda, T; Mizuno, K; Teusink-Cross, A; Mehta, PA; Marsh, RA; Kashuba, AD M; Vinks, AA; Davies, SM. Biology of Blood and Marrow Transplantation. 2016; 22:1829-1835.

Bortezomib for refractory autoimmunity in pediatrics. Khandelwal, P; Davies, SM; Grimley, MS; Jordan, MB; Curtis, BR; Jodele, S; Marsh, R; Filipovich, AJ. Biology of Blood and Marrow Transplantation. 2014; 20:1654-1659.